Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Benign Prostatic Hyperplasia Patient is able and willing to comply with all the assessments of the study 2. Patient or patient's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form 3. ≥ 45 years of age 4. Baseline IPSS score > 13 5. Prostate volume 25 cc and prostatic urethral length between 2.5-4.5 cm measured within the past 90 days 6. Failed, intolerant, or patient choice to not take a medication regimen for the treatment of LUTS  Obstructive intravesical median prostatic lobe which in the opinion of the operator would not benefit from treatment 2. Urethral stricture, meatal stenosis, or bladder neck obstruction either current, or recurrent requiring 2 or more dilations as reported in the patient's history 3. Requiring self-catheterization to void. 4. Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer 5. Any of the following, taken from a single uroflowmetry reading: 1. Post-void residual volume (PVR) > 250 ml 2. Peak urinary flow rate of > 15 ml/second 3. < 125 ml urinary volume voided at baseline (pre-bladder urinary volume of ≥150 ml required) 6. Other condition or disease that might cause urinary retention 7. History of other diseases causing voiding dysfunction 8. Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following successful treatment of UTI and a clean urine test), or subjects who have a history of recurrent or chronic UTIs (defined as 2 or more UTIs in the past 12 months) 9. Concomitant bladder stones 10. Previous pelvic irradiation or radical pelvic surgery 11. Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate 12. Chronic prostatitis, or recurring prostatitis within the past 12 months 13. Known allergy to nickel 14. Life expectancy less than 24 months 15. Use of concomitant medications (e.g., anticholinergics, antispasmodics or tricyclic antidepressants) affecting bladder function 16. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy not prohibited). 17. Taking 5-alpha-reductase inhibitors within 3 months of pre-treatment (baseline) evaluation 18. Taking one of the following within 2 weeks of pre-treatment (baseline) evaluation: 1. alpha-blockers, 2. imipramine, 3. anticholinergics, or 4. cholinergic medication gonadotropin releasing hormonal analogs 19. Taking androgens, unless evidence of eugonadal state for at least 6 months. 20. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation: 1. phenylephrine, or 2. pseudoephedrine 21. Future fertility concerns 22. Any concurrent medical condition or illness that might prevent study completion or would confound study results